Cargando…

Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen

Every year, around 127,000 people in Germany die as a result of smoking tobacco. These include 85,000 people with tobacco-related cancer. However, about a quarter of the adult population in Germany still smokes—often even when a tobacco-related disease develops. Many smokers do not achieve abstinenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Leuteritz, Katja, Zebralla, Veit, Wirtz, Hubert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895064/
http://dx.doi.org/10.1007/s12312-022-01055-x
_version_ 1784662827390205952
author Leuteritz, Katja
Zebralla, Veit
Wirtz, Hubert
author_facet Leuteritz, Katja
Zebralla, Veit
Wirtz, Hubert
author_sort Leuteritz, Katja
collection PubMed
description Every year, around 127,000 people in Germany die as a result of smoking tobacco. These include 85,000 people with tobacco-related cancer. However, about a quarter of the adult population in Germany still smokes—often even when a tobacco-related disease develops. Many smokers do not achieve abstinence without support. This article provides an overview of evidence-based tobacco cessation strategies and also describes the potential of tobacco cessation in the context of adjuvant therapy for tumor diseases. Finally, health policy challenges for tobacco cessation care are highlighted. A variety of psychological and pharmacological intervention methods for tobacco cessation are effective. Patients who smoke with tobacco-related diseases should be offered tobacco cessation therapy. As an adjuvant therapy in cancer treatment, it is comparatively inexpensive, with significant benefits for disease recovery and quality of life for those affected. To date, however, it has been offered in Germany only as a poorly regulated preventive measure. Tobacco cessation is of great importance as an adjuvant therapy for tumor diseases. In order to improve the quality of life of a large number of people with tobacco-related diseases, as well as for health economic reasons, it is urgently necessary that it become established and financed as a nationwide routine process in medical care.
format Online
Article
Text
id pubmed-8895064
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-88950642022-03-04 Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen Leuteritz, Katja Zebralla, Veit Wirtz, Hubert Forum Fokus Every year, around 127,000 people in Germany die as a result of smoking tobacco. These include 85,000 people with tobacco-related cancer. However, about a quarter of the adult population in Germany still smokes—often even when a tobacco-related disease develops. Many smokers do not achieve abstinence without support. This article provides an overview of evidence-based tobacco cessation strategies and also describes the potential of tobacco cessation in the context of adjuvant therapy for tumor diseases. Finally, health policy challenges for tobacco cessation care are highlighted. A variety of psychological and pharmacological intervention methods for tobacco cessation are effective. Patients who smoke with tobacco-related diseases should be offered tobacco cessation therapy. As an adjuvant therapy in cancer treatment, it is comparatively inexpensive, with significant benefits for disease recovery and quality of life for those affected. To date, however, it has been offered in Germany only as a poorly regulated preventive measure. Tobacco cessation is of great importance as an adjuvant therapy for tumor diseases. In order to improve the quality of life of a large number of people with tobacco-related diseases, as well as for health economic reasons, it is urgently necessary that it become established and financed as a nationwide routine process in medical care. Springer Medizin 2022-03-04 2022 /pmc/articles/PMC8895064/ http://dx.doi.org/10.1007/s12312-022-01055-x Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Fokus
Leuteritz, Katja
Zebralla, Veit
Wirtz, Hubert
Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen
title Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen
title_full Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen
title_fullStr Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen
title_full_unstemmed Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen
title_short Tabakkonsum und Behandlung von Tabakabhängigkeit: Wirksame Strategien und aktuelle Entwicklungen
title_sort tabakkonsum und behandlung von tabakabhängigkeit: wirksame strategien und aktuelle entwicklungen
topic Fokus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895064/
http://dx.doi.org/10.1007/s12312-022-01055-x
work_keys_str_mv AT leuteritzkatja tabakkonsumundbehandlungvontabakabhangigkeitwirksamestrategienundaktuelleentwicklungen
AT zebrallaveit tabakkonsumundbehandlungvontabakabhangigkeitwirksamestrategienundaktuelleentwicklungen
AT wirtzhubert tabakkonsumundbehandlungvontabakabhangigkeitwirksamestrategienundaktuelleentwicklungen